Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes

Schizophrenia Research

Volumn 137, Issue 1-3, 2012, Pages 66-72

  Martínez Cengotitabengoa, Mónica ^a,b   Mac Dowell, Karina Soledad ^a,c   Leza, Juan Carlos ^a,c   Micó, Juan Antonio ^a,d   Fernandez, Miryam ^a,b   Echevarría, Enrique ^e   Sanjuan, Julio ^a,f   Elorza, Julián ^a,d   González Pinto, Ana ^a,b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b Hospital Santiago   (Spain)

^c Universidad Complutense and Instituto de Investigación Hospital 12 de Octubre ^*  (Spain)

^d UNIVERSITY OF CÁDIZ   (Spain)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^f UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cognition; First episode; Inflammation; MCP 1; Oxidative stress; Psychosis

Indexed keywords

CATALASE; CHEMOKINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRITE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; EXECUTIVE FUNCTION; FEMALE; HUMAN; INFLAMMATION; LEARNING; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCHOSIS; VERBAL MEMORY; WORKING MEMORY;

ADULT; CASE-CONTROL STUDIES; CATALASE; CHEMOKINE CCL2; COGNITION DISORDERS; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; LINEAR MODELS; LIPID PEROXIDATION; MALE; NEUROPSYCHOLOGICAL TESTS; NITRITES; OXIDATIVE STRESS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; STATISTICS, NONPARAMETRIC; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 84860835844     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.03.004     Document Type: Article

References (76)

1. Addington J., Brooks B.L., Addington D. Cognitive functioning in first episode psychosis: initial presentation. Schizophr. Res. 2003, 62:59-64.
2. Adibhatla R.M., Hatcher J.F. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal 2010, 12(1):125-169.
3. Aiguo W., Zhe Y., Gomez-pinilla F. Vitamin E protects against oxidative damage and learning disability after mild traumatic brain injury in rats. Neurorehabil. Neural Repair 2010, 24(3):290-298.
4. American Psychiatric Association DSM-IV. Diagnostic and Statistical Manual of Mental Disorders 1994, (Washington, D.C.).
5. Behrens M.M., Sejnowski T.J. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?. Neuropharmacology 2009, 57(3):193-200.
6. Bitanihirwe B.K.Y., Woo T.-U.W. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 2011, 35:878-893.
7. Cabungcal J.H., Preissmann D., Delseth C., Cuenod M., Do K.Q., Schenk F. Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: relevance to schizophrenia. Neurobiol. Dis. 2007, 26(3):634-645.
8. Calabrese V., Scapagnini G., Giuffrida Stella A.M., Bates T.E., Clark J.B. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem. Res. 2001, 26(6):739-764.
9. Chowdari K.W., Bamne M.N., Nimgaonkar V.L. Genetic association studies of antioxidant pathway genes and schizophrenia. Antioxid. Redox Signal. 2011, 15:2037-2045.
10. Clausen A., Doctrow S., Baudry M. Prevention of cognitive deficits and brain oxidative stress with superoxide dismutase/catalase mimetics in aged mice. Neurobiol. Aging 2010, 31(3):425-433.
11. Conductier G., Blondeau N., Guyon A., Nahon J.L., Rovere C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J. Neuroimmunol. 2010, 224:93-100.
12. Cruz R., Almaguer Melian W., Bergado Rosado J.A. Glutathione in cognitive function and neurodegeneration. Rev. Neurol. 2003, 36(9):877-886.
13. Cui K., Luo X., Xu K., Ven Murthy M.R. Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical antioxidants. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(5):771-799.
14. Dean O., Bush A.I., Berk M., Copolov D.L., van den Buuse M. Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. Behav. Brain Res. 2009, 198(1):258-262.
15. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 2009, 29:313-326.
16. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007, 93:261-265.
17. Dickinson D., Harvey P.D. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr. Bull. 2009, 35:403-414.
18. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 2000, 12(10):3721-3728.
19. Do K.Q., Cabungcal J.H., Frank A., Steullet P., Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr. Opin. Neurobiol. 2009, 19:220-230.
20. Ebadi M., Brown-Borg H., Ren J., Sharma S., Shavali S., El ReFaey H., Carlson E.C. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr. Drug Targets 2006, 7(11):1513-1529.
21. Evola M., Hall A., Wall T., Young A., Grammas P. Oxidative stress impairs learning and memory in apoE knockout mice. Pharmacol. Biochem. Behav. 2010, 96(2):181-186.
22. Fendri C., Mechri A., Khiari G., Othman A., Kerkeni A., Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale 2006, 32(2 Pt 1):244-252.
23. Fett A.K., Viechtbauer W., Dominguez M.D., Penn D.L., van Os J., Krabbendam L. The relationship between neurocognitiion and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci. Biobehav. Rev. 2011, 35:573-588.
24. Galimberti D., Fenoglio C., Lovati C., Venturelli E., Guidi I., Corrà B., Scalabrini D., Clerici F., Mariani C., Bresolin N., Scarpini E. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol. Aging 2006, 27(12):1763-1768.
25. Gimeno D., Marmot M.G., Singh-Manoux A. Inflammatory markers and cognitive function in middle-aged adults: the Whitehall II study. Psychoneuroendocrinology 2008, 33(10):1322-1334.
26. Golden C.J. Stroop Color and Word Test: A Manual for Clinical and Experimental Uses 1978, Stoelting Co., Wood Dale, IL.
27. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70:1078-1090.
28. Golse B., Debray-Ritzen P., Puget K., Michelson A.M. Analysis of platelet superoxide dismutase 1 in the development of childhood psychoses. Nouv. Presse Med. 1977, 6(27):2449.
29. Golse B., Debray-Ritzen P., Puget K., Michelson A.M. Erythrocyte and platelet levels of superoxide dismutases (1 and 2) and glutathione peroxidase in developmental child psychoses. Nouv. Presse Med. 1978, 7(22):1952.
30. Golse B., Debray-Ritzen P., Durosay P., Puget K., Michelson A.M. Alterations in two enzymes: superoxide dismutase and glutathion peroxidase in developmental infantile psychosis (infantile autism). Rev. Neurol. (Paris) 1978, 134(11):699-705. (author's transl).
31. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 1982, 126(1):131-138.
32. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., Fenton W.S., Frese F., Goldberg T.E., Heaton R.K., Keefe R.S., Kern R.S., Kraemer H., Stover E., Weinberger D.R., Zalcman S., Marder S.R. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 2004, 56:301-307.
33. Heaton R.K. The Wisconsin Card Sorting Test 1981, Psychological Assessment Resources, Odessa, FL.
34. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficits in schizphrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
35. Henkel J.S., Engelhardt J.I., Siklos L., Simpson E.P., Kim S.H., Pan T., Goodman J.C., Siddique T., Beers D.R., Appel S.H. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 2004, 55:221-235.
36. Jahshan C., Heaton R.K., Golshan S., Cadenhead K.S. Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology 2010, 24:109-120.
37. Kadhim H.J., Duchateau J., Sebire G. Cytokines and brain injury: invited review. J. Intensive Care Med. 2008, 23(4):236-249.
38. Kubera M., Obuchowicz E., Goehler L., Brzeszcz J., Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:744-759.
39. Law A., Gauthier S., Quirion R. Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res. Brain Res. Rev. 2001, 35(1):73-96.
40. Lee K.S., Chung J.H., Lee K.H., Shin M.J., Oh B.H., Lee S.H., et al. Plasma levels of monocyte chemotactic protein 3 and beta-nerve growth factor increase with amnestic mild cognitive impairment. Cell. Mol. Immunol. 2009, 6(2):143-147.
41. Li H.C., Chen Q.Z., Ma Y., Zhou J.F. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J. Zhejiang Univ. Sci. B 2006, 7(12):981-986.
42. Liu Z.W., Zhang T., Yang Z. Involvement of nitric oxide in spatial memory deficits in status epilepticus rats. Neurochem. Res. 2007, 32(11):1875-1883.
43. Mangialasche F., Polidori M.C., Monastero R., Ercolani S., Camarda C., Cecchetti R., et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res. Rev. 2009, 8(4):285-305.
44. Marini J.C., Broussard S.R. Hyperammonemia increases sensitivity to LPS. Mol. Genet. Metab. 2006, 88(2):131-137.
45. Marioni R.E., Strachan M.W., Reynolds R.M., Lowe G.D., Mitchell R.J., Fowkes F.G., et al. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 2010, 59(3):710-713.
46. Mico J.A., Rojar-Corrales M.O., Gibert-Rahola J., Parellada M., Moreno D., Fraguas D., Graell M., et al. Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry 2011, 11(1):26.
47. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009, 63(3):257-265.
48. Monteiro de Almeida S., Letendre S., Zimmerman J., Lazzaretto D., McCutchan A., Ellis R. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J. Neuroimmunol. 2005, 169(1-2):144-152.
49. Muller N., Schwarz M.J. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(Suppl. 2):97-106.
50. Mundo E., Altamura A.C., Vismara S., Zanardini R., Bignotti S., Randazzo R., et al. MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2005, 132(1):1-4.
51. Olson L., Humpel C. Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Exp. Gerontol. 2010, 45(1):41-46.
52. Ozcan M.E., Gulec M., Ozerol E., Polat R., Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int. Clin. Psychopharmacol. 2004, 19(2):89-95.
53. Pae C.U. Monocyte chemoattractant protein-1 (MCP1) may play a role in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(1):313-314.
54. Pae C.U., Kim J.J., Yu H.S., Lee C.U., Lee S.J., Jun T.Y., et al. Monocyte chemoattractant protein-1 promoter -2518 polymorphism may have an influence on clinical heterogeneity of bipolar I disorder in the Korean population. Neuropsychobiology 2004, 49(3):111-114.
55. Pae C.U., Chung K.I., Kim J.J., Yu H.S., Lee S.J., Lee C., et al. Monocyte chemoattractant protein-1 promoter-2518 polymorphism and schizophrenia in the Korean population. Psychiatr. Genet. 2004, 14:65-67.
56. Patanella A.K., Zinno M., Quaranta D., Nociti V., Frisullo G., Gainotti G., et al. Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients. J. Neurosci. Res. 2010, 88:1106-1112.
57. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003, 121(2):109-122.
58. Reddy R., Sahebarao M.P., Mukherjee S., Murthy J.N. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol. Psychiatry 1991, 30(4):409-412.
59. Reddy R., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr. Res. 2003, 62(3):205-212.
60. Rothenburg L.S., Herrmann N., Swardfager W., Black S.E., Tennen G., Kiss A., et al. The relationship between inflammatory markers and post stroke cognitive impairment. J. Geriatr. Psychiatry Neurol. 2010, 23(3):199-205.
61. Ruiz de Azúa S., Matute C., Stertz L., Mosquera F., Palomino A., de la Rosa I., et al., in press. Plasma BDNF levels, learning capacity and cognition in patients with first episode psychosis. Psychol. Med.
62. Salter M., Duffy C., Garthwaite J., Strijbos P.J. Ex vivo measurement of brain tissue nitrite and nitrate accurately reflects nitric oxide synthase activity in vivo. J. Neurochem. 1996, 66(4):1683-1690.
63. Slosman D.O., Ludwig C., Zerarka S., Pellerin L., Chichero C., de Ribaupierre A., et al. Brain energy metabolism in Alzheimer's disease: 99mTc-HMPAO SPECT imaging during verbal fluency and role of astrocytes in the cellular mechanism of 99mTc-HMPAO retention. Brain Res. Brain Res. Rev. 2001, 36(2-3):230-240.
64. Solfrizzi V., D'Introno A., Colacicco A.M., Capurso C., Todarello O., Pellicani V., et al. Circulating biomarkers of cognitive decline and dementia. Clin. Chim. Acta 2006, 364(1-2):91-112.
65. Spreen O., Strauss E.A. A Compendium of Neuropsychological Test: Administration, Norms and Commentary 1998, Oxford University Press, New York.
66. Tanuma N., Sakuma H., Sasaki A., Matsumoto Y. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol. 2006, 112(2):195-204.
67. Thompson W.L., Karpus W.J., Van Eldik L.J. MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J. Neuroinflammation 2008, 5:35.
68. Uranova N.A., Zimina I.S., Vikhreva O.V., Krukov N.O., Rachmanova V.I., Orlovskaya D.D. Ultrastructural damage of capillaries in the neocortex in schizophrenia. World J. Biol. Psychiatry 2010, 11(3):567-578.
69. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin. Neurosci. 2010, 64(3):217-230.
70. Wechsler D. Wechsler Adult Intelligence Scale (WAIS-III) 1997, The Psychological Corporation, San Antonio, TX.
71. Wechsler D. Wechsler Memory Scale (WMS-III) 1997, The Psychological Corporation, San Antonio, TX.
72. Wilson C.J., Finch C.E., Cohen H.J. Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J. Am. Geriatr. Soc. 2002, 50(12):2041-2056.
73. Xu Y., Zhang J.J., Xiong L., Zhang L., Sun D., Liu H. Green tea polyphenols inhibit cognitive impairment induced by chronic cerebral hypoperfusion via modulating oxidative stress. J. Nutr. Biochem. 2010, 21(8):741-748.
74. Yaffe K., Lindquist K., Penninx B.W., Simonsick E.M., Pahor M., Kritchevsky S., et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61(1):76-80.
75. Yang G., Meng Y., Li W., Yong Y., Fan Z., Ding H., Wei Y., Luo J., Ke Z.J. Neuronal MCP-1 mediates microglia recruitment and neurodegeneration induced by the mild impairment of oxidative metabolism. Brain Pathol. 2011, 21:279-297.
76. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006, 81(2-3):291-300.